Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration  by Bamford, Nigel S. et al.
Neuron
ArticleRepeated Exposure to Methamphetamine Causes
Long-Lasting Presynaptic Corticostriatal Depression
that Is Renormalized with Drug Readministration
Nigel S. Bamford,1,2,3,* Hui Zhang,4 John A. Joyce,1 Christine A. Scarlis,1 Whitney Hanan,1 Nan-Ping Wu,5
Ve´ronique M. Andre´,5 Rachel Cohen,5 Carlos Cepeda,5 Michael S. Levine,5 Erin Harleton,4 and David Sulzer4,6,7
1Department of Neurology
2Center on Human Development and Disability
University of Washington, Seattle, WA 98105, USA
3Department of Pediatrics and Psychology, University of Washington and Children’s Hospital and Regional Medical Center,
Seattle, WA 98105, USA
4Departments of Neurology, Psychiatry, and Pharmacology, Columbia University College of Physicians and Surgeons,
New York, NY 10032, USA
5Mental Retardation Research Center, The David Geffen School of Medicine, University of California, Los Angeles,
Los Angeles, CA 90095, USA
6Center for Neurobiology and Behavior, Columbia University College of Physicians and Surgeons,
New York, NY 10032, USA
7Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
*Correspondence: bamford@u.washington.edu
DOI 10.1016/j.neuron.2008.01.033SUMMARY
Addiction-associated behaviors such as drug craving
and relapse are hypothesized to result from synaptic
changes that persist long after withdrawal and are
renormalized by drug reinstatement, although such
chronic synaptic effects have not been identified.
We report that exposure to the dopamine releaser
methamphetamine for 10 days elicits a long-lasting
(>4 month) depression at corticostriatal terminals
that is reversed by methamphetamine readmin-
istration. Both methamphetamine-induced chronic
presynaptic depression and the drug’s selective
renormalization in drug-experienced animals are in-
dependent of corresponding long-term changes in
synaptic dopamine release but are due to alterations
in D1 dopamine and cholinergic receptor systems.
These mechanisms might provide a synaptic basis
that underlies addiction and habit learning and their
long-term maintenance.
INTRODUCTION
Substance abuse is a chronic relapsing disorder in which drug
reinstatement, even long after withdrawal, is thought to return
the addict to a more stable, renormalized state (Ahmed and
Koob, 2005; Koob, 1992; Redish, 2004). How drugs produce
long-lasting neuroplastic changes and how relapse provides
compensation remain unknown, although a relationship between
dopamine and corticostriatal synaptic activity is strongly impli-
cated (Pessiglione et al., 2006; Vanderschuren and Kalivas,
2000). Most addictive drugs acutely increase synaptic dopamine,and, in the case of the psychostimulants methamphetamine and
amphetamine, do so via stimulation-independent, nonvesicular
reverse transport through the dopamine transporter and by inhib-
iting reuptake (Sulzer et al., 2005). The glutamatergic corticostria-
tal inputs are critical for the expression of behavioral and motoric
responses (McFarland et al., 2003; Pessiglione et al., 2006;
Pierce et al., 1996), and animals repeatedly exposed to psycho-
stimulants exhibit enhanced behavioral responses to drug rein-
statement long after withdrawal (Bickerdike and Abercrombie,
1997; Brady et al., 2005), with long-lasting reductions in basal
extracellular glutamate and augmented glutamate release from
corticostriatal inputs when the drugs are reinstated (McFarland
et al., 2003; Pierce et al., 1996). Very long-lasting presynaptic
effects of dopamine on the corticostriatal inputs that could con-
tribute to habit formation, addiction, or allostatic renormalization
have not been reported, and we have taken advantage of new
optical approaches to identify such changes.
RESULTS
Repeated Methamphetamine Induces Chronic
Presynaptic Depression
To directly examine release from cortical terminals within the
striatum (Figure 1A), we used the fluorescent tracer FM1-43
with multiphoton confocal microscopy in murine slice prepara-
tions. Stimulation of axons or cell bodies of projection neurons
in layers 5–6 of the M1 motor cortex resulted in endocytosis of
FM1-43 dye by recycling synaptic vesicles, revealing linear en
passant arrays of fluorescent puncta characteristic of cortico-
striatal afferents (Bamford et al., 2004a, 2004b). Following dye
loading, cortical restimulation resulted in exocytosis of FM1-43
dye from the terminals, decreasing in a manner approximating
first-order kinetics characteristic of synaptic vesicle fusion (Fig-
ure 1B). The kinetics of corticostriatal release were characterizedNeuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 89
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Corticostriatal NeuroplasticityFigure 1. CPD
(A) In this simplified striatal microcircuit, dopaminergic (DA) nigrostriatal fibers and cholinergic (ACh) interneurons modulate excitatory glutamatergic (GLU)
corticostriatal projections on medium spiny neurons. Neurotransmitter release is modified by D1 and D2 DA receptors, M2 and M4 muscarinic receptors and
a7*- and b2*-nicotinic receptors.
(B) Multiphoton images of corticostriatal terminals obtained from the forelimb motor striatum, located 1.0–1.5 mm from the site of cortical stimulation. Images
captured every 21.5 s reveal en passant arrays of corticostriatal terminals. Restimulation at t = 0 with 10 Hz pulses shows activity-dependent destaining of
fluorescent puncta. Bar, 2 mm.
(C) Amphetamine (Amph; 2 mg/kg i.p.)-elicited locomotor activity measured by ambulation summed over 90 min was determined in mice following repeated treat-
ment with saline or methamphetamine (Meth) for 10 days. Repeated Meth produced a 1370%–1970% increase in Amph-elicited ambulation through 140 days of90 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.
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Corticostriatal Neuroplasticityby the half-time (t1/2), which is defined as the time required for
terminal fluorescence to decay to half of its initial value.
We examined possible effects of repeated and intermittent
methamphetamine administration on corticostriatal release. Be-
cause the effects of methamphetamine and amphetamine on
striatal dopamine transmission are identical and are not discrim-
inated by humans, we chose methamphetamine, which is more
widely available to drug abusers, to use for in vivo administration
in mice. Mice were treated with saline (controls) or methamphet-
amine once per day (20 mg/kg/day i.p.) for 10 consecutive days.
This dose of methamphetamine may mimic plasma levels
reached with self-administration during ‘‘binges’’ (Davidson
et al., 2005). Consistent with previous reports (Bickerdike and
Abercrombie, 1997; Brady et al., 2005), repeated treatment
with methamphetamine induced an enhanced locomotor
response to an amphetamine challenge (2 mg/kg i.p.), 1–140
days following treatment (Figures 1C and 1D; p < 0.001). In these
mice, repeated treatment with methamphetamine inhibited cor-
ticostriatal release (Figures 1E–1G), producing a highly pro-
longed state of corticostriatal depression in which the t1/2 for re-
lease increased by 63%–90% during withdrawal (Figures 1H and
1I), an effect we term chronic presynaptic depression (CPD).
When half-times from individual terminals are presented relative
to their standard deviation from the mean value, a straight line
indicates a normally distributed (or single) population (Bamford
et al., 2004b). Repeated treatment with methamphetamine pro-
duced CPD by inhibiting release from all terminals, shifting the
population to a distribution that remained mostly normal
(Figure 1I).
Drug Reinstatement Reverses CPD
We then examined corticostriatal activity during psychostimu-
lant readministration. In saline-treated controls, we found
a 33% ± 12% depression of corticostriatal release in striatal
slices prepared from mice challenged with a single dose of
methamphetamine (20 mg/kg i.p., 30 min before death) in vivo
(t1/2 = 273 versus 203 s for controls; Figure 2A; p < 0.05). In strik-
ing contrast to controls, a methamphetamine challenge in vivo
10 days following repeated methamphetamine exposure par-
tially reversed CPD and potentiated release by 15% ± 2%
(t1/2 = 335 versus 285 s following challenge; Figure 2A; p < 0.05),
an effect we term paradoxical presynaptic potentiation (PPP).
Amphetamine also induced PPP in mice treated with a lower re-
peated dose of methamphetamine (t1/2 = 258 s; 10 mg/kg/day,10 d; Figure 2B) and did so by potentiating release from all termi-
nals (Figures 2C and 2D).
Repeated Methamphetamine Abolishes
Frequency-Dependent Inhibition
Our previous studies demonstrated that the magnitude of
dopamine’s inhibitory effect on corticostriatal activity is depen-
dent on cortical stimulation frequency (Bamford et al., 2004b).
We observed the effect of frequency-dependence by unloading
corticostriatal terminals at 1 Hz, 10 Hz, and 20 Hz before and
after an amphetamine challenge (10 mM) in vitro. In saline-treated
controls, amphetamine produced slower average unloading
half-times at 10 Hz and 20 Hz (p < 0.001) but not at 1 Hz
(p > 0.5; Figure 2E). The magnitude of dopamine inhibition be-
came progressively greater at higher corticostriatal stimulation
frequencies, with a 6% inhibition for the mean t1/2 values at
1 Hz (360/340 s), a 26% inhibition at 10 Hz (276/203 s), and
a 36% inhibition at 20 Hz (275/175 s; p < 0.001 for interaction be-
tween amphetamine and stimulation frequency; F(2,1253) = 7.6;
two-way ANOVA). As such, dopamine provides low-pass fre-
quency filtering at corticostriatal terminals.
On withdrawal day 10 following repeated treatment with meth-
amphetamine (20 mg/kg/day, 10 days), terminal release was de-
pressed at 10 and 20 Hz (p < 0.001, repeated-measures ANOVA;
Figure 2F). Amphetamine in vitro accelerated release by 19% at
1 Hz (320/259 s) and 13% at 10 Hz (318/277 s) but had no effect
at 20 Hz (276/276 s; p < 0.05 for interaction between amphet-
amine and stimulation frequency; F(2,1033) = 5.3; two-way
ANOVA). Thus, in contrast to controls, where the greatest inhibi-
tory effect of dopamine was seen at higher frequencies of stimu-
lation, repeated treatment with methamphetamine produced the
largest excitatory effect of dopamine at lower stimulation fre-
quencies. Regardless of treatment or stimulation frequency, re-
lease closely approximated first-order kinetics (r2 > 0.99; see
Figure S1 available online).
The depression in release following repeated treatment with
methamphetamine was not due to inadequate FM1-43 loading
of the recycling synaptic vesicle pool, because loading stimula-
tion frequencies of 1 Hz, 10 Hz, or 20 Hz (for 10 min) did not sig-
nificantly affect unloading at 10 Hz either in saline-treated con-
trols (t1/2 = 221 s at 1 Hz, 203 s at 10 Hz, and 234 s at 20 Hz;
data not shown; n = 82–391 puncta; p > 0.5, Mann-Whitney) or
following repeated treatment with methamphetamine (t1/2 =
300 s at 1 Hz, 318 s at 10 Hz, and 311 s at 20 Hz; data not shown;withdrawal (p < 0.001, t test with Bonferroni correction), significantly higher than in saline-treated mice challenged with saline (F(5,70) = 19; n = 8 mice per condition;
p < 0.001). Repeated Meth also produced a 12%–219% increase in ambulations, compared with saline-treated mice also receiving Amph challenges (F(5,70) = 8.5;
p < 0.001, repeated-measures ANOVA), although the difference between the two treatments narrowed after withdrawal day 20 (**p < 0.01, ***p < 0.001, ANOVA).
All values are mean ± SE.
(D) Amph-elicited locomotor activity 10 days following repeated Meth was higher and of longer duration, compared with responses from saline-treated mice chal-
lenged with Amph (F(17,238) = 9.1; n = 8 mice per condition; p < 0.001, repeated-measures ANOVA).
(E) Time-intensity analysis of FM1-43 destaining from individual puncta (n = 8) in slices from saline-treated mice. Stimulation begins at t = 0 s.
(F) FM1-43 destaining is depressed 10 days following repeated Meth.
(G) Mean ± SE florescence intensity of puncta shown in panels E and F demonstrates preservation of first-order release kinetics following repeated saline or Meth.
The plateau line represents fluorescence measurements in the absence of stimulation.
(H) Repeated Meth inhibits corticostriatal release half-times (t1/2) over 140 days of withdrawal (n = 4 mice per condition; *p < 0.05, **p < 0.01, t test with Bonferroni
correction).
(I) Individual terminal responses from panel H are represented in a normal probability plot. All terminals were depressed during withdrawal.
Values are mean ± SE.Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 91
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(A) A Meth challenge in vivo decreases corticostriatal release in saline-treated controls (higher destaining half-time) but increases release on withdrawal day 10
following repeated Meth (n = 185–325 puncta per condition; ***p < 0.01 versus control without Meth; !! p < 0.01 versus withdrawal without Meth, Mann-Whitney).
(B) Repeated Meth at 10 and 20 mg/kg/day inhibits individual terminal responses on withdrawal day 10. An Amph challenge 10 days following repeated Meth at
10 mg/kg/day (C) and 20 mg/kg/day (D) potentiated release from all terminals. Release half-times (t1/2) in slices from control (E) and Meth-treated mice (F) on
withdrawal day 10 following cortical stimulation at 1 Hz, 10 Hz, and 20 Hz in the presence and absence of Amph in vitro (n = 136–381 puncta for each condition;
***p < 0.001, Mann-Whitney).
Values are mean ± SE.n = 70–149 puncta; p > 0.1, Mann-Whitney). Furthermore, the
number of active terminals in each slice was similar following
each loading frequency (data not shown) and in both controls
(38.1 ± 4 puncta) and withdrawal (31.5 ± 3 puncta; p = 0.12,
ANOVA). The reduced fractional release of label during exocyto-
sis (Figure S2) could be due to a reduced probability of recycling
synaptic vesicles that undergo exocytic fusion per stimulus, a
reduced amount of FM1-43 released per exocytic event, or
a combination of these mechanisms.
Dopamine Release Is Normal
in Methamphetamine-Treated Mice
We explored whether these repeated methamphetamine-
induced changes in corticostriatal release relied on long-term
changes in dopamine transmission. PPP could not depend on
changes in dopamine neuronal firing, because it was measured
in the striatal slice from which dopamine cell bodies were absent,
but repeated treatment with methamphetamine might produce
long-lasting changes in dopamine terminals. To test this possi-
bility, we examined electrically evoked dopamine release and re-
uptake using cyclic voltammetry in the same preparation. Mice
were treated repeatedly with saline or methamphetamine
(20 mg/kg/day, 10 days). On withdrawal days 1, 10, 30, and 140,92 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.striatal slice preparations containing presynaptic dopamine ter-
minals were stimulated by a single electrical pulse, and the con-
centration and kinetics of dopamine release and reuptake were
measured at subsecond resolution using fast-scan cyclic vol-
tammetry, as described elsewhere (Zhang and Sulzer, 2004).
The only significant difference between saline- and metham-
phetamine-treated mice in response to a single pulse stimulus
was on withdrawal day 1, when evoked dopamine release was
depressed by 57% (2.3 mM dopamine versus 1.3 mM dopamine
for controls and methamphetamine-treated mice, respectively;
Figure S3A; p < 0.01). There was no change in evoked dopamine
release on withdrawal day 10, 30 and 140.
We further examined mice for alterations in synaptic short-
term presynaptic plasticity of the dopamine system. Dopamine
release in response to train stimulus emulating phasic firing
(4 pulses and 10 pulses at 100 Hz; Figure S3B) was not altered
on withdrawal day 1, 10, 30, or 140. The paired pulse ratio was
not altered (Figure S3C). The time constants for the fast compo-
nent (tf) and the slow component (ts) were 4.9 s and 16.7 s, re-
spectively, for withdrawal mice, and were no different from those
of controls (6.6 s and 16.5 s, respectively; p > 0.5).
To confirm that we were not examining effects due to
neurotoxicity in this protocol, mice were also treated with
Neuron
Corticostriatal Neuroplasticitymethamphetamine (10 mg/kg i.p.) four times at 2 hr intervals, an
established neurotoxic regimen. As expected on withdrawal day
10, dopamine release was reduced to 39% of control values by
this neurotoxic regimen (0.84 mM dopamine versus 2.14 mM do-
pamine for controls and mice treated with methamphetamine
four times, respectively; Figure S3D; p < 0.001).
Finally, we examined amphetamine-induced dopamine re-
lease. The maximum level of striatal dopamine efflux reached
8 mM within 6–20 min (Figure S3E), similar to responses in un-
treated mice (Bamford et al., 2004b), confirming that a psycho-
stimulant challenge elicits typical maximum levels of dopamine
release during withdrawal. Thus, although effects of metham-
phetamine on dopamine release apparently initiate CPD, the
maintenance of CPD and PPP was apparently not due to changes
in the ability of nigrostriatal terminals to release dopamine.
The lack of alterations in dopamine reuptake, short-term pre-
synaptic plasticity, or the concentration of dopamine released
by amphetamine detected during withdrawal indicates that re-
peated treatment with methamphetamine induces no long-last-
ing presynaptic alterations in dopamine neurotransmission.
Thus, although increased dopamine transmission due to meth-
amphetamine may have initiated long-term changes, the mainte-
nance of CPD and the ability to produce PPP during withdrawal
did not rely on an ongoing presynaptic alteration of dopamine
transmission. The results further indicate that the protocols
had no long-term neurotoxic effect on dopamine terminals.
Psychostimulants Filter Corticostriatal
Release via D2 Receptors
Our previous results in the striatum of untreated mice showed
that amphetamine inhibited exocytosis from less active
corticostriatal terminals via activation of D2 receptors (D2Rs)
(Bamford et al., 2004a, 2004b). In saline-treated mice, a metham-
phetamine challenge in vivo depressed corticostriatal exocytosis
(t1/2 = 272 s versus 201 s for controls; Figures 3A and 3B; p <
0.05). Similarly, acute amphetamine in vitro also decreased cor-
ticostriatal release (t1/2 = 263 s versus 203 s for untreated slices;
data not shown; n = 188–305 puncta; p < 0.001, Mann-Whitney).
In controls, the D2R antagonist sulpiride (10 mM) in vitro slightly
potentiated terminal release (t1/2 = 179 s versus 201 s without
sulpiride; Figure 3B; p > 0.5), indicating some tonic activation
of inhibitory D2R. However, sulpiride completely blocked inhibi-
tion by a methamphetamine challenge (t1/2 = 194 s versus 272 s
for methamphetamine in vivo with and without sulpiride in vitro;
Figures 3A and 3B and Figure S4; p < 0.001). A methamphet-
amine challenge in vivo created two reversible populations of ter-
minals that diverged at 1 standard deviation below the mean,
preferentially inhibiting slow-releasing terminals (80%; Fig-
ure 3C). Thus, a methamphetamine challenge in vivo or amphet-
amine in vitro produced a D2R-dependent filter with filtering
applied preferentially to terminals with the lowest probability of
release.
D2Rs Remain Inhibitory
in Methamphetamine Withdrawal
We determined the effect of repeated treatment with metham-
phetamine on D2R-mediated corticostriatal filtering. On with-
drawal day 10 following repeated treatment with methamphet-amine, a methamphetamine challenge in vivo produced PPP
(t1/2 = 335 s versus 285 s following the challenge; Figures 3D
and 3E; p < 0.05). Similarly, an amphetamine challenge in vitro
also potentiated release on withdrawal days 1–140 (Figures 3F
and 3G).
On withdrawal day 10, sulpiride slightly potentiated terminal
release (t1/2 = 299 s versus 335 s without sulpiride; Figure 3E;
p > 0.3). However, it enhanced, rather than reversed PPP follow-
ing a methamphetamine challenge in vivo, increasing cortico-
striatal release to control values (t1/2 = 227 s; Figures 3D and
3E; p > 0.5 versus controls). Sulpiride also enhanced PPP due
to amphetamine in vitro, potentiating release to control values
(t1/2 = 203 s; p > 0.5) on withdrawal days 1–140 (Figures 3F
and 3G and Figure S4). Thus, in animals repeatedly treated
with methamphetamine, a methamphetamine challenge in vivo
or an amphetamine challenge in vitro induced PPP to partially
normalize corticostriatal release, and PPP completely reversed
CPD once D2R inhibition was blocked. The results demonstrated
that PPP was not due to an activation of D2Rs, because these
receptors continued to be inhibitory during withdrawal.
CPD Is Reversed through D1 Receptor Actions
An alternate possibility is that psychostimulant activation of D1
receptors (D1Rs) might induce PPP. As in our previous studies
(Bamford et al., 2004a, 2004b), the D1R agonist SKF38393
(10 mM; t1/2 = 186 s versus 203 s without SKF38393; p > 0.5) or
antagonist SCH23390 (10 mM; t1/2 = 193 s; p > 0.5) had little effect
on corticostriatal release in saline-treated controls (Figures 4A
and 4B). Furthermore, SCH23390 had no effect on corticostriatal
release even when dopamine was released by amphetamine
(t1/2 = 262 s versus 262 s without SCH23390; Figure 4B;
p > 0.5). Thus, D1R stimulation did not significantly affect cortico-
striatal activity under control conditions.
In marked contrast, on withdrawal day 10 following repeated
treatment with methamphetamine, the D1R agonist SKF38393
strongly potentiated release and partially reversed CPD (t1/2 =
233 s versus 318 s without SKF38393; Figures 4C and 4D;
p < 0.001) by renormalizing the activity of the faster-releasing ter-
minals (Figure 4E), whereas the D1R antagonist SCH23390 had
no effect (t1/2 = 313 s; Figures 4C–4E; p > 0.5). As expected,
SCH23390 largely blocked the excitatory response produced
with SKF38393 (t1/2 = 289 s for SCH23390 and SKF38393; data
not shown; n = 113 puncta; p > 0.5 versus SCH23390 alone,
Mann-Whitney). The combination of sulpiride and SKF38393 fur-
ther enhanced release and fully reversed CPD (t1/2 = 202 s; p > 0.5
versus untreated sections) by additionally accelerating exocyto-
sis from slower terminals (Figure 4E). Combined SKF38393 and
sulpiride also reversed CPD in mice treated with lower doses of
methamphetamine (10 mg/kg/day; t1/2 = 225 s versus 307 s with-
out SKF38393 and sulpiride; data not shown; n = 250 puncta;
p < 0.001, Mann-Whitney). Amphetamine-induced D1R activa-
tion was responsible for PPP, because PPP was reversed by
SCH23390 (t1/2 = 356 s; p < 0.001) even when sulpiride, which
might be expected to enhance release by blocking any lingering
D2R-mediated inhibition, was included with SCH23390 (t1/2 =
333 s; Figure 4D; p < 0.01). The excitatory effects of SKF38393
on amphetamine-induced PPP were not additive (t1/2 = 265 s;
p = 0.04 versus SKF38393 alone), and were identical toNeuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 93
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(A) In slices prepared from mice repeatedly treated with saline, a Meth challenge in vivo produced inhibition of FM1-43 destaining that was reversed by the D2R
antagonist sulpiride (Sulp) in vitro.
(B) Distribution of mean t1/2 of release for FM1-43 destaining curves shown in panel A (n = 188–325 puncta; ***p < 0.001 versus untreated sections [Veh], Mann-
Whitney).
(C) Individual terminal responses in saline-treated controls following a challenge with Meth in vivo with and without Sulp. Repeated Meth produced more inhibition
at the slowest-releasing terminals (greater t1/2).
(D) On withdrawal day 10 following repeated Meth, a Meth challenge in vivo accelerated corticostriatal release. The addition of Sulp in vitro further accelerated
release to control half-times.
(E) Distribution of mean t1/2 for destaining curves shown in panel D (n = 149–362 puncta; **p < 0.01; ***p < 0.001 versus untreated sections [Veh], Mann-Whitney).
(F) On withdrawal day 10 following repeated Meth, Amph in vitro induced PPP while Amph in combination with Sulp normalized release.
(G) Following repeated Meth, Amph in vitro induced PPP over 140 days of withdrawal while Amph in combination with Sulp normalized release (n = 167–368
puncta for each condition; *p < 0.05, **p < 0.01 versus Veh from the same withdrawal day, Mann-Whitney).
Values are mean ± SE.amphetamine alone (t1/2 = 263 s; Figure 4D; p > 0.5). Together, the
results show that, although D1Rs have no effect on corticostriatal
release in controls, their actions become excitatory following
repeated treatment with methamphetamine. Amphetamine has
less excitatory effect than does the D1R agonist, because dopa-
mine would also inhibit release through presynaptic D2R actions.94 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.Locomotor Activity Is Dependent on a New D1R Effect
Because a psychostimulant challenge in withdrawal would pro-
duce striatal excitation and allow excessive locomotor responses
through a D1R-mediated pathway, blockade of this receptor
might prevent these sensitized behavioral responses. Consistent
with previous reports (Kuribara, 1995), we found that increasing
Neuron
Corticostriatal NeuroplasticityFigure 4. D1R Stimulation Reverses CPD
(A) Compared to untreated sections (Veh), the D1R agonist SKF38393 (SKF; n = 169 puncta) and antagonist SCH23390 (SCH; n = 386 puncta) in vitro had no effect
on release in controls following repeated saline.
(B) Distribution of mean t1/2 of release for destaining curves shown in panel A with additional experimental groups from controls. Compared to untreated sections
(Veh; n = 188 puncta), Amph (n = 305 puncta) inhibited release, but the D1R agonist SKF (n = 169 puncta) and antagonist SCH (n = 386 puncta) had no effect. In the
presence of Amph, SCH had no effect with (n = 116 puncta) or without SULP (n = 151 puncta; ***p < 0.001 versus Veh, Mann-Whitney).
(C) Ten days following repeated Meth (withdrawal), SKF accelerated release, whereas SCH had no effect.
(D) Distribution of mean t1/2 of release for destaining curves shown in panel C with additional experimental groups from withdrawal. Amph in vitro (n = 128 puncta)
boosted release to elicit PPP. SKF (n = 247 puncta) increased release to a greater extent than Amph, whereas SCH (n = 266 puncta) had no effect. SCH (n = 212
puncta) blocked the potentiating effect of Amph. SCH in combination with Sulp (n = 161 puncta) also blocked accelerated release by Amph, whereas SKF (n = 168
puncta) had little effect on PPP produced by Amph (*p < 0.05, **p < 0.01; ***p < 0.001 versus Veh; n = 149 puncta; Mann-Whitney).
(E) Individual terminal responses to D1 and D2R manipulation in withdrawal.
(F) Mice were treated with Meth (20 mg/kg/day i.p.) for 10 days. An Amph challenge (2 mg/kg i.p.) on withdrawal day 10 induced sensitized locomotor ambulations
summed over 90 min. The D1R antagonist SCH inhibited this locomotor response (*p < 0.001; n = 8 mice per treatment group) with a significant linear trend over
dose levels (r2 = 0.97).
(G) Interval locomotor responses for treatment groups in panel F.
(H) Additional mice were treated with saline for 10 days. Ten days later, these mice were treated with the D1R antagonist SCH and were challenged with saline.
There were small variations in locomotor activity but at the doses used, SCH had no effect on locomotor activity (p = 0.48; n = 8 mice per treatment group;
r2 = 0.01).
Values are mean ± SE.Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 95
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s.c.; 30 min before an amphetamine challenge) produced
a dose-dependent reduction in locomotor responses to an am-
phetamine challenge (2 mg/kg) on withdrawal day 10 (Figures
4F and 4G; p < 0.001), but had no effect on saline-treated controls
(Figure 4H; p > 0.5). Thus, both augmentation of corticostriatal
release and enhanced locomotion are dependent on a new
D1R effect that is seen only following repeated exposure to meth-
amphetamine.
CPD and PPP Are Mediated through
Acetylcholine Receptors
Although D1R activation reversed CPD and mediated PPP, the
results did not reveal where the responsible D1R was acting.
We suspected that CPD and PPP might be mediated indirectly
through cholinergic tonically active interneurons (TANs) that rep-
resent a small fraction of striatal neurons but provide the majority
of striatal acetylcholine (ACh) transmission. Amphetamine exerts
multiple state-dependent effects on striatal extracellular ACh
efflux (DeBoer and Abercrombie, 1996). TANs possess D1-
and D2-like receptors (DeBoer and Abercrombie, 1996; Yan
et al., 1997; Le Moine et al, 1991), and their activity mediates cor-
ticostriatal responses, including dopamine-dependent cortico-
striatal long-term depression (LTD) (Wang et al., 2006) via b2*
and a7* nicotinic receptors (nAChRs) on TANs (Azam et al.,
2003), a7* receptors found on corticostriatal terminals (Marchi
et al., 2002; Pakkanen et al., 2005; Wang and Sun, 2005) that ex-
ert tonic excitation, and M2 muscarinic ACh receptors (mAChRs)
that are inhibitory (Calabresi et al., 2000; Hersch et al., 1994; Vol-
picelli-Daley et al., 2003; Zhang et al., 2002). nAChRs are rapidly
desensitized at high agonist levels, in which case the agonists
prevent tonic excitation and thus inhibit release (Wooltorton
et al., 2003).
In slices from saline-treated mice, bath application of ACh
(1–100 mM) potently inhibited release (Figure 5A), consistent
with either mAChR-mediated depression and/or a desensitiza-
tion of tonically activated nAChR (Quick and Lester, 2002). We
determined that tonic ACh in controls was excitatory because
vesamicol (5 mM), a potent inhibitor of vesicular ACh uptake, in-
hibited corticostriatal release in controls (t1/2 = 298 s; n = 135
puncta; data not shown; p < 0.001, Mann-Whitney) to a degree
similar to CPD (318 s; p > 0.5, Mann-Whitney).
These cholinergic receptor responses were markedly altered
by repeated treatment with methamphetamine. Low concentra-
tions of bath-applied ACh reversed CPD in withdrawal and
accelerated release beyond control half-times (t1/2 = 178 s at
10 mM ACh versus 203 s for controls; Figures 5A and 5B; p <
0.05), suggesting a sensitized excitatory response to exogenous
ACh. ACh also accelerated release on withdrawal day 10 follow-
ing a lower daily dose of methamphetamine (10 mg/kg/day, 10 d;
Figure 5A). Higher concentrations of ACh (>50 mM), which were
expected to desensitize nAChR (Quick and Lester, 2002), in-
hibited release (Figure 5A). Although ACh depletion by vesamicol
inhibited release in controls, it had no effect on CPD (t1/2 = 332 s;
n = 126 puncta; Figure 5B; p > 0.5, Mann-Whitney), confirming
a loss of tonic excitatory ACh response in withdrawal.
Because reductions in tonic ACh can rapidly enhance striatal
nAChR (Pakkanen et al., 2005; Wooltorton et al., 2003; Zhou96 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.et al., 2001) and mAChR (Volpicelli-Daley et al., 2003) sensitivity,
we examined the effects of repeated treatment with metham-
phetamine on striatal tissue ACh content. In saline-treated
mice, a methamphetamine challenge (20 mg/kg i.p., 30 min be-
fore death) decreased ACh content by 35% (p < 0.05, t test),
whereas repeated treatment with methamphetamine decreased
striatal ACh during withdrawal by 46%–76% (p < 0.01), an effect
partially reversed following methamphetamine reinstatement
(Figure 5C; p < 0.05, t test).
Loss of Nicotinic Excitation Results in CPD
This methamphetamine-induced reduction in ACh would likely
perturb both nAChR and mAChR responses. In saline-treated
controls, the classic nAChR agonist, nicotine (5–500 nM), in-
hibited corticostriatal release (Figure 5D), consistent with the
compound’s ability to rapidly desensitize b2*-nAChR (Quick
and Lester, 2002; Wooltorton et al., 2003) and prevent ongoing
corticostriatal excitation by tonic ACh. Corticostriatal release is
dependent on tonic excitation by nAChR, because the nAChR
antagonist mecamylamine reduced release (10 mM; t1/2 = 295 s
versus 203 s for controls; n = 168 puncta; data not shown;
p < 0.001, Mann-Whitney). Tonic nAChR excitation appeared
to be due to actions at a7*-like nAChRs, because the a7* antag-
onist methyllycaconitine (20 nM) inhibited corticostriatal release
(t1/2 = 278 s; n = 186 puncta; p < 0.001, Mann-Whitney). Likewise,
choline (10 mM), an agonist that desensitizes a7*-nAChR
(Turner, 2004), inhibited release in slices from saline-treated con-
trols (t1/2 = 435 s versus 203 s for controls; n = 66 puncta; data
not shown; p < 0.001, Mann-Whitney). In addition, the b2*-
nAChR antagonist dihydro-b-erythroidine (DHbE; 300 nM) also
reduced release (t1/2 = 279 s; data not shown; n = 97 puncta;
p < 0.001, Mann-Whitney).
In contrast to controls, low concentrations of nicotine (5 nM)
10 days following repeated treatment with methamphetamine
reversed CPD (t1/2 = 200 s versus 203 s for controls; Figures
5D and 5E; p > 0.5, Mann-Whitney) via a strong excitatory re-
sponse that normalized release for all but the20% slowest ter-
minals (Figure 5F). As expected, this effect was blocked by the
b2*-nAChR antagonist DHbE (t1/2 = 317 s; n = 122 puncta; data
not shown; p > 0.5, Mann-Whitney). Similar to bath-applied
ACh, this potentiation was lost at higher nicotine levels (Figures
5D and 5F), consistent with b2*-nAChR desensitization (Wooltor-
ton et al., 2003). Tonic nAChR excitation was not observed in
methamphetamine withdrawal, because the nicotinic receptor
blocker mecamylamine (t1/2 = 295 s versus 318 s with and with-
out mecamylamine; Figures 5E and 5G; p > 0.5), the desensitiz-
ing a7*-nAChR agonist choline (t1/2 = 326 s; n = 127 puncta; data
not shown; p > 0.5, Mann-Whitney), and the b2*-nAChR antago-
nist DHbE (t1/2 = 302 s; n = 99 puncta; data not shown; p > 0.5,
Mann-Whitney) no longer inhibited release as they did in con-
trols. AChR-induced PPP occurred downstream of D1R action,
because mecamylamine blocked PPP elicited by the D1 agonist
SKF38393 (t1/2 = 233 s for SKF38393 versus 290 s for SKF38393
with mecamylamine; Figure 5G; p < 0.001) and by amphetamine
(t1/2 = 277 s for amphetamine versus 352 s for amphetamine with
mecamylamine; Figures 5G and 5H; p < 0.001) as did desensitiz-
ing nicotine levels (50 nM; t1/2 = 330 s for amphetamine and
nicotine; Figure 5H; p < 0.001).
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Corticostriatal NeuroplasticityFigure 5. CPD and PPP Are Regulated through nAChRs
(A) Terminal release over a range of acetylcholine (ACh) concentrations 10 days following repeated saline (control) and Meth (withdrawal; 10 and 20 mg/kg/day,
10 days; n = 30–381 puncta). Concentration dependence curves were fit with a Hill equation.
(B) Ten days following repeated Meth (20 mg/kg/day), vesamicol (VES) had little effect on CPD, while ACh potentiated release to a greater extent than controls.
(C) Striatal tissue concentrations of ACh, measured by HPLC, remained depressed during Meth withdrawal (*p < 0.01 versus untreated control mice; Veh; n = 8
slices from 4 mice; t test).
(D) In slices from control animals, increasing concentrations of nicotine (NIC) inhibited release (t1/2 = 240 s at IC50 = 3.52 nM; n = 104–299 puncta). Ten days
following repeated Meth, release was accelerated at low concentrations of NIC (5 nM) but higher concentrations of NIC rapidly decreased release (IC50 =
12.5 nM; n = 77–190 puncta).
(E) On withdrawal day 10, low NIC concentrations accelerated release, whereas the nAChR channel blocker mecamylamine (MEC) had little effect on CPD.
(F) Individual terminal responses during withdrawal for low (5 nM) and high (50 nM) concentrations of NIC.
(G) During withdrawal, MEC prevented potentiation of release by SKF and Amph (n = 149–247 puncta; ***p < 0.001, Mann-Whitney).
(H) Individual terminal responses during withdrawal demonstrate inhibition of Amph-induced PPP by both NIC and MEC (n = 60–188 puncta).
Values are mean ± SE.Muscarinic Receptors Become Sensitized
during Withdrawal
Next, we examined the effect of repeated treatment with meth-
amphetamine on mAChR responses. In slices from saline-
treated mice, the mAChR agonist muscarine (Figure 6A) inhibited
release, whereas the antagonist, atropine (1–20 mM) had no ef-fect (Figure 6B), indicating that tonic ACh did not inhibit cortico-
striatal activity via mAChR. Thus, in controls, tonic ACh exerted
no inhibition at mAChR while providing ongoing excitation at
nAChRs.
Muscarine continued to be inhibitory in withdrawal (Figure 6A)
but reached a maximum effect at a lower concentration (78% ofNeuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 97
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mum inhibition in withdrawal; Figure 6A; p < 0.001), consistent
with hypersensitive mAChR responses. However, atropine re-
versed CPD (Figures 6B and 6C) at all varicosities except the
slowest 20% of the population (Figure 6D), a state nearly iden-
tical to that following the D1 agonist, SKF38393 (Figure 4E), or
low concentrations of nicotine (Figure 5F) or ACh (10 mM; data
not shown).
Together, these data indicate that during withdrawal, low tonic
ACh levels were associated with sensitized responses by both
nAChR and mAChR. The sensitized mAChR response contrib-
uted to CPD and occurred downstream of D1R action, as atro-
pine (1 mM) reversed CPD in the presence of either SKF38393
or SCH23390 (Figure 6E). The mAChR response was upstream
of nAChR excitation, as both desensitizing concentrations of nic-
otine (50 nM; t1/2 = 310 s versus 196 s for atropine [10 mM] alone;
n = 131 puncta; p < 0.001, Mann-Whitney) and mecamylamine
(t1/2 = 324 s; data not shown; n = 101 puncta; p < 0.001,
Mann-Whitney) prevented atropine potentiation during with-
drawal. mAChR activation, however, played no role in PPP, be-
cause atropine did not block amphetamine excitation in with-
Figure 6. CPD Develops through Sensitized
mAChRs
(A) Terminal release over a range of muscarinic
(MUSC) concentrations from slices prepared
from saline-treated (control) and Meth-treated
mice (withdrawal) on withdrawal day 10. MUSC
inhibited release to a greater extent and at a lower
dose in withdrawal (t1/2 = 342 s at IC50 = 0.01 mM;
n = 57–176 puncta) than controls (t1/2 = 276 s at
IC50 = 0.38 mM; n = 86–265 puncta).
(B) Atropine (ATR) accelerated release (t1/2 = 263 s
at EC50 = 1.02 mM; n = 55–254 puncta) in with-
drawal but had no effect in controls (n = 77–254
puncta).
(C) ATR potentiated release in withdrawal.
(D) Individual terminal responses from withdrawal
mice with and without ATR (1 and 10 mM; n = 55–
381 puncta) are compared to controls.
(E) In the presence of ATR (1 mM; n = 155 puncta),
SKF (n = 94 puncta) and SCH (n = 142 puncta) had
little effect on corticostriatal release during Meth
withdrawal (**p < 0.01, ***p < 0.001 versus Veh,
Mann-Whitney).
Values are mean ± SE.
drawal (t1/2 = 278 s for amphetamine
versus 248 s with amphetamine and atro-
pine [10 mM]; data not shown; n = 128
puncta; p > 0.5, Mann-Whitney).
Thus, withdrawal mice selectively
exhibited two, long-lasting forms of
methamphetamine-induced presynaptic
corticostriatal plasticity. CPD is due to
a tonic inhibition mediated by reduced
tonic nAChR excitation combined with
a tonic mAChR inhibition, whereas PPP
is due to psychostimulant-induced D1
activation that boosts corticostriatal release by activating
nAChRs. These results are consistent with evidence that both
nAChR and mAChR sensitivity are strongly regulated by ACh in-
put, with low ACh levels generally promoting supersensitivity
(Overstreet and Djuric, 2001). This balance between opposing
ACh effects is altered by methamphetamine-induced sensitized
nAChR and mAChR responses. As was observed following sim-
ulation of PPP by low nicotine levels, withdrawal mice are very
sensitive to nAChR excitation, although higher nicotine or ACh
levels cause desensitization and eliminate PPP.
CPD and PPP in Postsynaptic Medium Spiny Neurons
We expected that changes in glutamate release from cortical
afferents during CPD and PPP would be reflected in postsynaptic
medium spiny neurons. Mice were treated with saline (n = 8) or
methamphetamine (20 mg/kg/day i.p.; n = 9) for 10 days. Record-
ings from medium spiny neurons in voltage-clamp mode (n = 28
from saline-treated mice and n = 31 from methamphetamine-
treated mice), obtained 10 days after the last injection, revealed
no differences in passive membrane properties between groups
(membrane capacitance, 97.5 ± 3.3 and 93.8 ± 2.4 pF; input98 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.
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Corticostriatal NeuroplasticityFigure 7. Response to CPD in Medium Spiny
Neurons
(A) Traces represent spontaneous (s) EPSCs in the pres-
ence of bicuculline (BIC, 10 mM, a GABAA receptor
blocker) alone (left) or BIC and tetrodotoxin (TTX; right) in
MSNs from saline- and Meth-treated animals at a holding
potential of 70 mV.
(B) In the presence of BIC only, there was a small but sig-
nificant reduction of sEPSCs in cells from Meth-treated
mice, compared with saline-treated mice. Histogram on
the right is a cumulative inter-event interval distribution
of sEPSCs. Intervals were significantly different (p < 0.05).
(C) In a subset of cells, TTX was added to isolate mEPSCs.
After TTX, there was a significant decrease in mEPSC
frequency in cells from Meth-treated, compared with sa-
line-treated mice. Histogram on the right is a cumulative
inter-event interval distribution of mEPSCs.
(D) Responses evoked in MSNs by stimulation of the cor-
tical layers in saline- and Meth-treated mice. More stimu-
lation intensity was needed to induce responses of similar
amplitude in cells from Meth-treated mice than in cells
from saline-treated mice. Traces represent the average
of three responses. The graph on the right indicates that
the threshold current required to induce responses was
significantly higher in cells from Meth-treated mice,
compared with saline-treated mice. Student’s t tests or
ANOVAs were used for group comparisons. Asterisks
indicate differences were statistically significant (p < 0.05).
Values are mean ± SE.resistance, 87.0 ± 4.4 and 92.9 ± 8.4 MU; time constant, 1.5 ± 0.1
and 1.6 ± 0.1 ms, respectively). The average frequency of spon-
taneous excitatory postsynaptic currents (sEPSCs; Figure 7A
[left] and Figure 7B) was higher in cells from saline-treated
mice, compared with methamphetamine-treated mice (1.17 ±
0.11 Hz and 0.94 ± 0.07 Hz; p = 0.036), providing electrophysio-
logical evidence supporting CPD. In a subset of cells (n = 6 from
saline-treated mice and n = 7 from methamphetamine-treated
mice) tetrodotoxin (TTX; 1 mM) was used to isolate miniature (m)
EPSCs (Figure 7A [right] and Figure 7C). In this group, the fre-
quency of sEPSCs also was significantly higher in saline-treated
mice than in methamphetamine-treated mice (p = 0.033). After
administration of TTX, the average frequency of mEPSCs
(Figure 7C) remained significantly higher (p = 0.047) in cells
from control mice (1.2 ± 0.2 Hz), compared with methamphet-
amine-treated mice (0.7 ± 0.1 Hz). Differences in frequency
were more dramatic after administration of TTX, indicating that
in the absence of this blocker, cortical pyramidal neuron firing
may be increased in methamphetamine-treated mice, compared
with controls, possibly as a compensatory mechanism. In con-
trast, average mEPSCs amplitudes were similar between groups
(10.4 ± 0.9 pA in cells from saline-treated mice and 8.8 ± 0.8 pA in
cells from methamphetamine-treated mice). This finding indi-
cates that inmethamphetamine-treated mice there was a depres-
sion of synaptic transmission in the corticostriatal pathway andthat this depression was independent of action potentials be-
cause it persisted in the presence of TTX. Evidence for reduced
glutamate transmission was also obtained from evoked EPSCs.
The current required to evoke EPSCs (Figure 7D) was significantly
higher in cells from methamphetamine-treated mice (0.46 ±
0.05 mA) than in cells from saline-treated mice (0.32 ± 0.04 mA)
(p = 0.021). The average evoked EPSC amplitude was determined
at threshold intensity +0.1 mA in cells from saline- and metham-
phetamine-treated mice. At 0.42 mA, the average EPSC ampli-
tude in control cells was 104.3 ± 11.7 pA (n = 18), and at
0.56 mA the amplitude in methamphetamine-treated cells was
93.3 ± 10.8 pA (n = 23). Thus, to obtain comparable responses,
higher intensities need to be used in methamphetamine-treated
mice than in control mice, providing further evidence of CPD.
To determine whether PPP also could be demonstrated in
postsynaptic neurons, amphetamine (10 mM) was bath applied
to examine its effects on sEPSCs. Amphetamine produced
a small reduction (3%) in average frequency of sEPSCs in cells
(n = 5) from saline-treated mice, whereas it significantly increased
the frequency (34%) in cells (n = 8) from methamphetamine-
treated mice (p = 0.02, Figure S5A). Furthermore, PPP was likely
mediated by D1Rs because bath application of the D1R agonist
SKF38393 (10 mM) produced no significant change (7% increase)
in the frequency of sEPSCs in cells (n = 6) from saline-treated
mice but significantly increased (34% increase) the frequencyNeuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 99
Neuron
Corticostriatal NeuroplasticityFigure 8. Proposed Mechanism for Meth-
amphetamine-Induced Synaptic Plasticity
(A) The simplified striatal circuit is composed of
MSNs that receive excitatory GLU corticostriatal
projections, modulatory DA nigrostriatal fibers,
and tonically active ACh-releasing interneurons
(TANs). ACh modulates GLU release (Malenka
and Kocsis, 1988) through excitatory a7*-nicotinic
(NIC) (Marchi et al., 2002; Pakkanen et al., 2005)
and inhibitory M2 mAChRs (Calabresi et al.,
2000) located on corticostriatal terminals (Hersch
et al., 1994) and regulates its own release through
M4 muscarinic (Zhang et al., 2002) and both
a7*-NIC and b2*-NIC autoreceptors (Azam et al.,
2003).
(B) Under control conditions, DA released by a psy-
chostimulant inhibits GLU release from a subset of
cortical terminals via D2R (Bamford et al., 2004b).
Although TANs possess both inhibitory D2R (Yan
et al., 1997) and excitatory D1R (Le Moine et al.,
1991; Yan et al., 1997), D2R responses predomi-
nate so that DA reduces ACh efflux from striatal
cholinergic interneurons (DeBoer and Abercrom-
bie, 1996).
(C) Following repeated Meth, a reduction in ACh
availability sensitizes muscarinic and nicotinic re-
ceptors. Enhanced muscarinic inhibition and re-
duced nicotinic excitation promotes CPD.
(D) During withdrawal, DA released by a psychosti-
mulant challenge induces PPP. DA increases ACh
efflux (Bickerdike and Abercrombie, 1997) through
TAN D1R responses (Berlanga et al., 2003) to
excite GLU release through a7*-nAChRs.in cells (n = 7) from methamphetamine-treated mice (p = 0.015;
Figure S5B). As expected, the D1R antagonist SCH23390
(1 mM) had no effect on the frequency of sEPSCs (n = 5 cells
from saline-treated mice and n = 6 cells from methamphet-
amine-treated mice; Figure S5C). In contrast, bath application
of the D2R antagonist sulpiride (10 mM) significantly increased
the frequency of sEPSCs in both groups (58% in saline-treated
mice and 28% in methamphetamine-treated mice; p = 0.007
and p = 0.015, respectively; Figure S5D). However, the addition
of amphetamine produced a further increase (12%) in cells from
methamphetamine-treated mice, whereas it reduced (10%) the
frequency in cells from control mice (data not shown). Overall,
these electrophysiological data support the optical recordings
of presynaptic release and demonstrate that CPD and PPP
produce alterations in the excitation of postsynaptic neurons.
DISCUSSION
We report that repeated methamphetamine treatment causes
long-lasting synaptic changes in the corticostriatal pathway
that were previously suggested by theoretical models to underlie
drug dependence. The CPD induced by the drug occurs at cor-
ticostriatal terminals and is independent of long-term changes in
striatal dopamine terminals. PPP by drug reinstatement occurs
both in vivo and in vitro exclusively in animals that have under-
gone withdrawal and acts to partially renormalize synaptic activ-
ity. Although the precise mechanisms underlying CPD and PPP
require elucidation, the data indicate that D1 dopamine and cho-100 Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc.linergic responses are required for these long-term adaptations
to drug administration.
CPD was indicated by a decreased rate of exocytosis of the
recycling synaptic vesicle pool in motor corticostriatal terminals
in mice repeatedly exposed to methamphetamine, together with
a reduction in spontaneous and mEPSCs, as well as by the
increased threshold required to evoke EPSCs in methamphet-
amine-treated mice. The optical recordings indicate that the
changes were presynaptic, whereas the electrophysiological re-
sults confirm a presynaptic locus, because they occurred in the
presence of TTX, and as the amplitude of mEPSCs was not dif-
ferent in cells from saline- or methamphetamine-treated mice.
PPP was clearly observed by the increased rate of exocytosis
of the recycling vesicle pool with psychostimulant reinstatement,
which occurred only in mice previously exposed to repeated
treatment with methamphetamine, as well as by the paradoxical
increase in sEPSCs after amphetamine and a D1R agonist, an
effect never observed in control conditions.
How might dopamine release during repeated treatment with
methamphetamine exert long-lasting changes in ACh transmis-
sion and initiate CPD and PPP without a concomitant long-last-
ing change in dopamine release? Opposing D1R-excitatory and
D2R-inhibitory mechanisms regulate cholinergic efflux in the
striatum (Bertorelli and Consolo, 1990; DeBoer and Abercrom-
bie, 1996), because TANs possess D2Rs that inhibit ACh release
(Yan et al., 1997) and D1Rs that enhance ACh efflux (Figure 8)
(Abercrombie and DeBoer, 1997; DeBoer and Abercrombie,
1996; Le Moine et al., 1991; Yan et al., 1997). Under control
Neuron
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tion of ACh efflux (DeBoer and Abercrombie, 1996). ACh accel-
erates corticostriatal release through a7*-nAChR (Marchi et al.,
2002; Pakkanen et al., 2005; Wang and Sun, 2005) and inhibits
corticostriatal release through M2 mAChRs (Calabresi et al.,
2000; Hersch et al., 1994), with mAChR responses submissive
to alterations in nAChR sensitivity (Wang and Sun, 2005). Our
data are consistent with dominant regulation by tonic nAChR in
control mice, because mAChR blockade by atropine did not af-
fect release, whereas nAChR blockade with mecamylamine,
ACh depletion with vesamicol, and desensitization of nAChR
by nicotine and choline all were inhibitory. The lack of tonic
ACh influence via mAChR on control corticostriatal activity is in
agreement with previous literature (Malenka and Kocsis, 1988).
It may be that the tonic levels of ACh are normally too low to de-
sensitize nAChR, but that when higher levels are reached, there
is an allosteric regulation of mAChRs which provides enhanced
affinity to ACh (Wang and Sun, 2005).
The situation in drug-naive animals is markedly altered in with-
drawal, possibly because repeated treatment with methamphet-
amine reduces ACh levels, limiting corticostriatal nAChR excita-
tion and sensitizing both mACh and nACh receptors (Siegal et al.,
2004). Persistent dopamine release during repeated treatment
with methamphetamine may additionally uncouple D1R/D2R
synergisms (Hu and White, 1994; Kashihara et al., 1999) on
TAN neurons, favoring D1R excitation (Berlanga et al., 2003) so
that methamphetamine challenge during withdrawal activates
TAN D1R and enhances ACh release (Bickerdike and Abercrom-
bie, 1997) to activate PPP. The dependence of PPP on D1R and
nAChR activation could contribute to the ability of D1 antago-
nists to block sensitized locomotor responses or drug self-
administration in rodents (Ciccocioppo et al., 2001).
Our data do not directly indicate the locus of AChRs responsi-
ble for methamphetamine-induced corticostriatal plasticity. The
nAChRs that mediate PPP may be on corticostriatal terminals
(Marchi et al., 2002; Pakkanen et al., 2005; Wang and Sun,
2005) or TANs (Azam et al., 2003). Likewise, the mAChRs re-
sponsible for CPD may also be at presynaptic sites (Calabresi
et al., 2000; Hersch et al., 1994), on TANs (Zhang et al., 2002),
or elsewhere. The mAChR may be an inhibitory TAN autorecep-
tor (Zhang et al., 2002), since nAChR stimulation is required to
reverse CPD.
An advantage of presynaptic optical measurements is that
variability between individual presynaptic terminals can be ana-
lyzed. Our FM1-43 loading protocol is fairly extensive (10 min,
10 Hz), and saturates those terminals capable of dye uptake
(i.e., additional stimulation results in no additional labeled termi-
nals). Because CPD in withdrawal is reversed by pharmacologi-
cal treatment following loading, it is not due to a decreased num-
ber of active terminals or a smaller pool of recycling synaptic
vesicles but rather a decreased probability of fusion of recycling
vesicles. A decreased probability of synaptic vesicle fusion is
consistent with the decreased mEPSC frequency in the pres-
ence of TTX following withdrawal.
The distribution of individual cortical terminal half-times in con-
trols demonstrated that stimulation of D2R during periods of high
cortical activity depresses release from the majority of cortical
terminals, preferentially inhibiting the activity of the terminalswith the lowest probability of release, an effect that occurs in
the dynamic and kinetic range of dopamine input associated
with both salient behavioral stimuli and psychostimulants (Bam-
ford et al., 2004b). Thus, dopamine release associated with
salience during learning would reinforce specific corticostriatal
connections by filtering out less-effective cortical terminal inputs
(Bamford et al., 2004b). Repeated treatment with methamphet-
amine would disrupt this filtering mechanism by inducing CPD.
The induction of CPD is dopamine dependent, but CPD continues
to be expressed even when dopamine release returns to normal.
This indicates that long-lasting plasticity, once initiated, does not
require a corresponding long-lasting change in the dopamine
system. Subsequent psychostimulant readministration, how-
ever, would enhance striatal ACh release by activating D1R,
and thus induce PPP by accelerating exocytosis from cortico-
striatal terminals. PPP provides a mechanism by which drug
readministration renormalizes synaptic function following with-
drawal, a feature long suggested to be required for addiction,
and may favor the conversion of LTD to LTP (Nishioku et al.,
1999). Because striatal LTD and LTP are implicated in memory
for habitual behaviors (Jog et al., 1999; Packard and Knowlton,
2002), these findings support the idea that the striatum is likely
to be the site for storage of information related to locomotor
sensitization and drug addiction (Gerdeman et al., 2003; Koob,
1992).
EXPERIMENTAL PROCEDURES
Animals and Statistics
Experimental procedures were performed in accordance with the USPHS
Guide for Care and Use of Laboratory Animals and were approved by the Insti-
tutional Animal Care and Use Committee at the University of Washington, Co-
lumbia University, and UCLA. C57BL/6 mice aged 12–16 weeks were obtained
from Jackson Labs (Bar Harbor, ME). Mice were treated with methamphetamine
(10 or 20 mg/kg/day, i.p.) or with an equal volume of 0.9% saline by daily injec-
tion for 10 days. In some studies, mice were challenged by a single dose of
methamphetamine (20 mg/kg, i.p.) or amphetamine (2 mg/kg i.p.) in vivo.
Mice were anesthetized with Nembutal or ketamine/xylazine before death.
Mice for electrochemical recordings were treated in University of Washington
and shipped to Columbia University. Some mice were treated at Columbia Uni-
versity to exclude possible effects of stress. For in vivo studies, mice were sac-
rificed 30 min following administration of methamphetamine, when dopamine
efflux is expected to reach peak concentrations (McFarland et al., 2003). To en-
sure equilibrium, sections were exposed to pharmacological agents for 10 min
before stimulation-mediated unloading. All drugs were obtained from Sigma (St.
Louis, MO).
Values given in the text and in the figures are mean ± SE. To establish differ-
ences in FM1-43 release between groups of mice exposed to saline or meth-
amphetamine, release half-times from each mouse were averaged, and signif-
icance was determined by use of the t test with Bonferroni correction
(n = number of mice). Differences between nonparametric release half-times
(t1/2) following receptor perturbation were determined using the Mann-Whitney
test (n = number of puncta). Comparisons between groups of puncta represent
data collected from 4–6 mice, and comparisons between groups of mice rep-
resent the average of 149–439 puncta from 6–12 slices per mouse. Differences
were considered significant at levels of p < 0.05. Changes in terminal subpop-
ulations were determined graphically using normal probability plots by
comparing individual terminal release to normally distributed data.
Behavioral Protocol
Locomotor responses were determined using animal activity monitor cages,
as described in the Supplemental Data.Neuron 58, 89–103, April 10, 2008 ª2008 Elsevier Inc. 101
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Optical recordings of cortical afferents in the motor striatum were obtained as
described elsewhere (Bamford et al., 2004a) and are further detailed in the
Supplemental Data.
Electrochemical Recordings with Cyclic Voltammetry
Striatal dopamine release was studied in 3–5 pairs of methamphetamine-
treated mice and their saline-treated controls for each withdrawal day (i.e.,
day 1, day 10, day 30, and day 140), using fast-scan cyclic voltammetry. Elec-
trochemical recordings and electrical stimulation were adapted from previous
studies (Schmitz et al., 2001), and the procedures are described further in the
Supplemental Data.
Detection of Striatal ACh Concentrations
ACh tissue concentrations were determined by high-performance liquid chro-
matography, based on a reaction with acetylcholinesterase and choline
oxidase (Vanderbilt Kennedy Center, Vanderbilt, TN), according to previous
publications (Bertrand et al., 1994; Damsma et al., 1985), as further described
in the Supplemental Data.
Electrophysiology
Electrophysiological recordings in medium spiny neurons were obtained as
described elsewhere (Cepeda et al., 1998) and are further detailed in the
Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/58/1/89/DC1/.
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